Drugs / SCB-420
last change Jan 2023 re-read 2 minutes ago

SCB-420

Developed for
wet macular degeneration
Investigated by
Clover Biopharmaceuticals AUS Pty

Trials 1 · a red edge is where a trial was stopped

2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04919096 Apr → Sep 2022 wet macular degeneration Clover Biopharmaceuticals AUS Pty Withdrawn No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as SCB-420 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04919096